|
Market Closed -
Xetra
23:35:32 02/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 359.10 EUR | -2.41% |
|
+0.01% | +28.11% |
| 10-03 | AbbVie joins US government pilot to test drug discount rebates | RE |
| 09-30 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 126,718 | 140,139 | 154,142 | 140,103 | 176,250 | 217,896 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 23.63% | - | - |
| Enterprise Value (EV) 1 | 151,990 | 169,779 | 207,811 | 188,229 | 221,725 | 259,382 | 253,713 | 248,710 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 16.98% | -2.19% | -1.97% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 25.5x | 22.8x | 21.9x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 19.3x | 15.7x | 12.7x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.3x | 2x | 5.28x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 5.6x | 5.41x | 5.23x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 6.66x | 6.29x | 5.97x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 11.9x | 11.4x | 11.1x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 15.3x | 14.3x | 13.5x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 23.3x | 17.2x | 16.2x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 4.28% | 5.81% | 6.19% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.5% | 2.64% | 2.76% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.83 | 17.67 | 18.41 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 63.7% | 60.3% | 60.4% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,938 | 40,309 | 41,654 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,864 | 22,213 | 22,322 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,964 | 17,686 | 18,396 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,581 | 9,393 | 9,971 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,485 | 35,817 | 30,814 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 403.04 | 403.04 | 403.04 |
| Nbr of stocks (in thousands) | 563,266 | 533,579 | 535,178 | 537,533 | 538,481 | 540,632 | - | - |
| Announcement Date | 7/2/22 | 31/1/23 | 6/2/24 | 4/2/25 | 3/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 410.8B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- AMG Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
